Skip to main content
Mark Vanderveken Toronto Lawyer

Mark Vanderveken

Associate Fasken
Jurisdiction Ontario, 2017
Language(s) English
Office(s) Toronto
Contact
Share
  • LinkedIn

Overview

Mark Vanderveken advises clients on regulatory compliance and intellectual property matters, with a particular focus on the life sciences industry.

Mark provides strategic guidance on the production and sale of regulated products, including pharmaceuticals, food, cosmetics, natural health products, and medical devices. He also assists clients with the protection and commercialization of intellectual property assets.

Mark articled with a global law firm before joining Fasken, and was seconded to a leading pharmaceutical company during his articling term. He is a graduate of the University of Toronto, Faculty of Law.

Achievements

Client Work

  • ATB Securities Inc. leads private placement of senior secured convertible debentures of The Cannabist Company Holdings Inc., [Deal - ATB Securities Inc.], Cultivator, manufacturer and provider of cannabis products and related services, completes private placement offering.
  • Research Capital Corporation leads bought deal public offering of Medexus Pharmaceuticals Inc., [Deal - Research Capital Corporation], Bought deal public offering of units for specialty pharmaceutical company.
  • Dignio AS indirectly acquires the assets of AceAge Inc., a Canadian health technology company, [Deal - Dignio AS], Norwegian health technology company acquires the assets of a Canadian manufacturer of medication dispensers
  • Voxtur Analytics Corp. completes C$4.4 million arm's length acquisition of Municipal Tax Equity Consultants Inc. and the acquisition of MTE Paralegal Professional Corporation by its associated entity, [Deal - Voxtur Analytics Corp.], Transformational real estate technology company acquires provider of municipal finance support services
  • Algernon Pharmaceuticals Inc. completes C$1.1 million marketed public offering, [Deal - Algernon Pharmaceuticals Inc.], Clinical stage drug re-purposing company closes marketed public offering
  • Advanz Pharma Corp. Limited completes the acquisition of Intercept Pharmaceuticals, Inc., [Deal - ADVANZ PHARMA Corp. Limited], Speciality pharmaceutical company with a strategic focus on complex medicines acquires American biopharmaceutical company.
  • ADVANZ PHARMA Corp. Limited completes the acquisition of Intercept Pharmaceuticals, Inc.'s business in Europe, Canada, and all other markets outside of the U.S., [Deal - ADVANZ PHARMA Corp. Limited], Specialty pharmaceutical company with a strategic focus on complex medicines acquires the majority of the business and operations of a biopharmaceutical company
  • Skye Bioscience signs arrangement agreement to acquire Emerald Health Therapeutics in a share-for-share transaction, [Deal - Skye Bioscience Inc], Emerald is a Vancouver-based Canadian licensed cannabis producer that is exiting the cannabis sector and pivoting into the pharmaceutical sector. Skye Bioscience is a US-based biopharmaceutical company focused on development of proprietary cannabinoid derivatives for medical treatment of various diseases.
  • Echelon Wealth Partners Inc. leads C$2.36 million financing for VOTI Detection Inc., [Deal - Echelon Wealth Partners Inc.], Private placement for Canadian x-ray security system company

Career & Education

Education

  • JD University of Toronto
  • Certificate, Transnational Law University of Geneva
  • MSc, Environmental Physiology McMaster University
  • BSc (Hons), Biology McMaster University

Memberships & Affiliations

  • Canadian Bar Association
  • American Bar Association
  • Canadian Association of Professionals in Regulatory Affairs
  • IPIC Emerging Leaders Committee

Knowledge

Publications

    Subscribe

    Receive email updates from our team

    Subscribe